{
    "name": "budesonide inhaled",
    "comment": "Rx",
    "other_names": [
        "Pulmicort Respules",
        "Pulmicort Flexhaler"
    ],
    "classes": [
        "Corticosteroids",
        "Inhalants"
    ],
    "source": "https://reference.medscape.com/drug/pulmicort-respules-pulmicort-flexhaler-budesonide-inhaled-343428",
    "pregnancy": {
        "common": [
            "There are no adequate well-controlled studies in pregnant women; however, there are published studies on use of budesonide, in pregnant women; studies of pregnant women have not shown that inhaled budesonide increases risk of abnormalities when administered during pregnancy",
            "There are no well-controlled human studies that have investigated effects of therapy during labor and delivery"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, therapy, administered by subcutaneous route, caused structural abnormalities, was embryocidal, and reduced fetal weights in rats and rabbits at less than maximum recommended human daily inhalation dose (MRHDID), but these effects were not seen in rats that received inhaled doses approximately 2 times the MRHDID; experience with oral corticosteroids suggests that rodents are more prone to structural abnormalities from corticosteroid exposure than humans",
                    "In women with poorly or moderately controlled asthma, there is increased risk of several perinatal adverse outcomes such as preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in neonate; pregnant women with asthma should be closely monitored and medication adjusted as necessary to maintain optimal asthma control"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no available data on effects of therapy on breastfed child or on milk production; budesonide, is present in human milk; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Status asthmaticus, acute bronchospasm"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Respiratory tract tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, ocular herpes simplex",
                "Risk of more serious or fatal course of chickenpox or measles in susceptible patients (eg, unvaccinated or immunologically unexposed individuals); care must be taken to avoid exposure",
                "Localized infections with Candida albicans in mouth and pharynx in some patients; mouth must be rinsed after inhalation to reduce risk",
                "Deaths from adrenal insufficiency have occurred after abrupt withdrawal of oral steroids; taper withdrawal gradually",
                "Potential decrease in growth velocity in children",
                "Immunocompromised patients",
                "Hepatic impairment",
                "Risk of infections of nose and pharynx, including C albicans",
                "Decrease in bone mineral density after long-term administration of corticosteroids; monitor patients at risk",
                "Excessive use may suppress hypothalamic-pituitary-adrenal function; monitor closely, especially postoperatively or during periods of stress",
                "During periods of stress or severe status asthmaticus, supplementary systemic corticosteroids may be immediately required",
                "Not to be administered for rapid relief of acute bronchospasm (agent is not a bronchodilator)",
                "Nasal septum perforation, wheezing",
                "Cataracts, glaucoma, increased intraocular pressure",
                "Risk of systemic eosinophilic conditions, some consistent with Churg-Strauss syndrome"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Respiratory infection",
            "percent": "34-38"
        },
        {
            "name": "Rhinitis",
            "percent": "7-12"
        },
        {
            "name": "Otitis media",
            "percent": "1-12"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "10"
        },
        {
            "name": "Nasal congestion",
            "percent": "3"
        },
        {
            "name": "Pharyngitis",
            "percent": "3"
        },
        {
            "name": "Allergic rhinitis",
            "percent": "2"
        },
        {
            "name": "Viral gastroenteritis",
            "percent": "2"
        },
        {
            "name": "Viral upper respiratory tract infection",
            "percent": "2"
        },
        {
            "name": "Oral candidiasis",
            "percent": "1"
        }
    ]
}